{
    "info": {
        "nct_id": "NCT05011188",
        "official_title": "A Phase 1b/2 Study of FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer",
        "inclusion_criteria": "1. Histologically confirmed metastatic prostate adenocarcinoma.\n2. Disease progression by PCWG3 criteria at study entry.\n3. Prior progression by PCWG3 criteria on one or more androgen signaling inhibitors including abiraterone acetate, enzalutamide, apalutamide, and/or darolutamide.\n4. No prior taxane-based chemotherapy for the treatment of mCRPC. Prior taxane use in the castration-sensitive prostate cancer (CSPC) setting allowed provided last dose > 6 months prior to study entry.\n5. Patients must be evaluable for the primary endpoint of composite response, and must have either serum PSA ≥ 2 ng/mL during Screening and/or measurable disease by RECIST 1.1 criteria.\n6. Participants must be willing to undergo metastatic tumor biopsy during Screening. If there is no safely accessible metastatic lesion, this requirement will be waived.\n7. Dose Expansion only: Participants must be willing to undergo CD46-directed Positron Emission Tomography (PET) imaging during Screening (Co-enrolling on NCT05245006, Groups B and C)\n8. Castrate level of serum testosterone at study entry (<50 ng/dL). Patients without prior bilateral orchiectomy are required to remain on Luteinizing hormone-releasing hormone (LHRH) analogue treatment for duration of study.\n9. No other systemic anti-cancer therapies administered other than LHRH analogue within 14 days or, 5 half-lives, whichever is shorter, prior to initiation of study treatment. Adverse events related to prior anti-cancer treatment related to therapies other than LHRH analogue must have recovered to Grade ≤ 1 with the exception of any grade alopecia. a. Patients receiving enzalutamide prior to study entry may continue treatment at their current enzalutamide dose level without requirement for wash-out period.\n10. Age >=18 years.\n11. Eastern Cooperative Oncology Group (ECOG) performance status <= 1 (Karnofsky performance status >= 70 percent (%)).\n12. Demonstrates adequate organ function as defined below:\n\n    1. Absolute neutrophil count ≥ 1,500/microliter (mcL).\n    2. Platelets >= 100,000/mcL and no platelet transfusions during the 14 days prior to first dose of FOR46.\n    3. Hemoglobin >= 8.0 grams per deciliter (g/dL) without red blood cell transfusion during the 14 days prior to first dose of FOR46.\n    4. Total bilirubin <=1.5 x institutional upper limit of normal (ULN), unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits.\n    5. Aspartate aminotransferase (AST) /serum glutamic-oxaloacetic transaminase (SGOT) <=3 x institutional institutional upper limit of normal (ULN).\n    6. Alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) =3 x ULN.\n    7. Serum creatinine <= 1.5 x institutional upper limit of normal OR Calculated creatinine clearance glomerular filtration rate (GFR) >= 60 mL/min, calculated using the Cockcroft-Gault equation.\n    8. Serum sodium level >=130 mmol/L.\n13. Ability to understand a written informed consent document, and the willingness to sign it.\n14. Individuals with concurrent second malignancy requiring active treatment at study entry. Nonmelanoma skin cancer, non-muscle invasive bladder cancer, and other carcinomas-in-situ are allowable exceptions.\n15. Patients must agree to use adequate contraception prior to the study, for the duration of study participation, and 60 days after last administration of study treatment. Adequate contraception includes:\n\n    1. Patients who are sexually active should consider their female partner to be of childbearing potential if she has experienced menarche and is not postmenopausal (defined as amenorrhea > 24 consecutive months) or has not undergone successful surgical sterilization. Even women who use contraceptive hormones (oral, implanted, or injected), an intrauterine device, or barrier methods (diaphragms, condoms, spermicide) should be considered to be of childbearing potential.\n    2. Acceptable methods of contraception include continuous total abstinence, or double-barrier method of birth control (e.g. condoms used with spermicide, or condoms used with oral contraceptives). Periodic abstinence and withdrawal are not acceptable methods of contraception.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Has received prior radiotherapy within 2 weeks of first dose of FOR46.\n2. Prior treatment with FOR46 or another CD46-targeting therapeutic agent.\n3. Prior histologic evidence of de novo or treatment-emergent small cell neuroendocrine prostate cancer. Pathologic assessment of baseline tumor biopsy performed during Screening is not required for determination of study eligibility.\n4. Cardiac condition as defined as one or more of the following:\n\n   1. Uncontrolled supraventricular arrhythmia or ventricular arrhythmia requiring treatment.\n   2. New York Heart Association (NYHA) congestive heart failure class III or IV.\n   3. History of unstable angina, myocardial infarction, or cerebrovascular accident within 6 months prior to Cycle 1, Day 1.\n5. History of seizure or pre-disposing condition including:\n\n   1. History of brain metastasis.\n   2. Cerebrovascular accident (CVA) within 6 months prior to study entry.\n   3. History of intracranial hemorrhage.\n6. History of pneumonitis.\n7. Is receiving systemic steroid therapy at a prednisone equivalent dose of > 10 milligram daily or other form of immunosuppressive therapy within 7 days prior to first dose of study drug.\n8. Has an active infection requiring intravenous antibiotics within 7 days prior to Cycle 1, Day 1.\n9. Use of a prohibited concomitant medication within 7 days of first dose of FOR46, including:\n\n   a. Strong inhibitor of CYP3A4 (boceprevir, clarithromycin, cobicistat, conivaptan, diltiazem, danoprevir/ritonavir, elvitegravir/ritonavir, grapefruit juice, idelalisib, indinavir/ritonavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, paritaprevir/ritonavir/ombitasvir and/or dasabuvir, posaconazole, ritonavir, saquinavir/ritonavir, tipranavir/ritonavir, troleandomycin, and voriconazole).\n10. Major surgery within 28 days prior to Cycle 1, Day 1. Minor procedures including biopsies, dental surgery, cataract surgery, or outpatient procedure are allowed.\n11. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n12. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "2. Disease progression by PCWG3 criteria at study entry.",
                "criterions": [
                    {
                        "exact_snippets": "Disease progression by PCWG3 criteria at study entry",
                        "criterion": "disease progression (by PCWG3 criteria)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Disease progression by PCWG3 criteria at study entry",
                        "criterion": "disease progression (by PCWG3 criteria)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at study entry"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Disease progression by PCWG3 criteria at study entry",
                        "criterion": "disease progression (by PCWG3 criteria)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Disease progression by PCWG3 criteria at study entry",
                        "criterion": "disease progression (by PCWG3 criteria)",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at study entry"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) =3 x ULN.",
                "criterions": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) =3 x ULN",
                        "criterion": "alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) =3 x ULN",
                        "criterion": "alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Aspartate aminotransferase (AST) /serum glutamic-oxaloacetic transaminase (SGOT) <=3 x institutional institutional upper limit of normal (ULN).",
                "criterions": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) /serum glutamic-oxaloacetic transaminase (SGOT) <=3 x institutional institutional upper limit of normal (ULN)",
                        "criterion": "aspartate aminotransferase (AST) / serum glutamic-oxaloacetic transaminase (SGOT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x institutional upper limit of normal (ULN)"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) /serum glutamic-oxaloacetic transaminase (SGOT) <=3 x institutional institutional upper limit of normal (ULN)",
                        "criterion": "aspartate aminotransferase (AST) / serum glutamic-oxaloacetic transaminase (SGOT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x institutional upper limit of normal (ULN)"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Ability to understand a written informed consent document, and the willingness to sign it.",
                "criterions": [
                    {
                        "exact_snippets": "Ability to understand a written informed consent document",
                        "criterion": "ability to understand written informed consent document",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign it",
                        "criterion": "willingness to sign informed consent document",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ability to understand a written informed consent document",
                        "criterion": "ability to understand written informed consent document",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign it",
                        "criterion": "willingness to sign informed consent document",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Histologically confirmed metastatic prostate adenocarcinoma.",
                "criterions": [
                    {
                        "exact_snippets": "Histologically confirmed metastatic prostate adenocarcinoma",
                        "criterion": "prostate adenocarcinoma",
                        "requirement": {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Histologically confirmed metastatic prostate adenocarcinoma",
                        "criterion": "prostate adenocarcinoma",
                        "requirement": {
                            "requirement_type": "metastatic status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Histologically confirmed metastatic prostate adenocarcinoma",
                        "criterion": "prostate adenocarcinoma",
                        "requirement": {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Histologically confirmed metastatic prostate adenocarcinoma",
                        "criterion": "prostate adenocarcinoma",
                        "requirement": {
                            "requirement_type": "metastatic status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Serum creatinine <= 1.5 x institutional upper limit of normal OR Calculated creatinine clearance glomerular filtration rate (GFR) >= 60 mL/min, calculated using the Cockcroft-Gault equation.",
                "criterions": [
                    {
                        "exact_snippets": "Serum creatinine <= 1.5 x institutional upper limit of normal",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x institutional upper limit of normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Calculated creatinine clearance glomerular filtration rate (GFR) >= 60 mL/min, calculated using the Cockcroft-Gault equation",
                        "criterion": "creatinine clearance glomerular filtration rate (GFR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Calculated creatinine clearance glomerular filtration rate (GFR) >= 60 mL/min, calculated using the Cockcroft-Gault equation",
                        "criterion": "creatinine clearance glomerular filtration rate (GFR)",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Serum creatinine <= 1.5 x institutional upper limit of normal",
                                "criterion": "serum creatinine",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x institutional upper limit of normal"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Calculated creatinine clearance glomerular filtration rate (GFR) >= 60 mL/min, calculated using the Cockcroft-Gault equation",
                                "criterion": "creatinine clearance glomerular filtration rate (GFR)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 60,
                                        "unit": "mL/min"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Calculated creatinine clearance glomerular filtration rate (GFR) >= 60 mL/min, calculated using the Cockcroft-Gault equation",
                                "criterion": "creatinine clearance glomerular filtration rate (GFR)",
                                "requirement": {
                                    "requirement_type": "calculation method",
                                    "expected_value": "Cockcroft-Gault equation"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. No other systemic anti-cancer therapies administered other than LHRH analogue within 14 days or, 5 half-lives, whichever is shorter, prior to initiation of study treatment. Adverse events related to prior anti-cancer treatment related to therapies other than LHRH analogue must have recovered to Grade ≤ 1 with the exception of any grade alopecia. a. Patients receiving enzalutamide prior to study entry may continue treatment at their current enzalutamide dose level without requirement for wash-out period.",
                "criterions": [
                    {
                        "exact_snippets": "No other systemic anti-cancer therapies administered other than LHRH analogue within 14 days or, 5 half-lives, whichever is shorter, prior to initiation of study treatment.",
                        "criterion": "systemic anti-cancer therapies (other than LHRH analogue)",
                        "requirement": {
                            "requirement_type": "administration timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adverse events related to prior anti-cancer treatment related to therapies other than LHRH analogue must have recovered to Grade ≤ 1 with the exception of any grade alopecia.",
                        "criterion": "adverse events from prior anti-cancer therapies (other than LHRH analogue)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adverse events related to prior anti-cancer treatment related to therapies other than LHRH analogue must have recovered to Grade ≤ 1 with the exception of any grade alopecia.",
                        "criterion": "adverse events from prior anti-cancer therapies (other than LHRH analogue)",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "alopecia (any grade)"
                        }
                    },
                    {
                        "exact_snippets": "Patients receiving enzalutamide prior to study entry may continue treatment at their current enzalutamide dose level without requirement for wash-out period.",
                        "criterion": "enzalutamide treatment prior to study entry",
                        "requirement": {
                            "requirement_type": "continuation allowed",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "No other systemic anti-cancer therapies administered other than LHRH analogue within 14 days or, 5 half-lives, whichever is shorter, prior to initiation of study treatment.",
                                "criterion": "systemic anti-cancer therapies (other than LHRH analogue)",
                                "requirement": {
                                    "requirement_type": "administration timing",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">",
                                                "value": 14,
                                                "unit": "days"
                                            },
                                            {
                                                "operator": ">",
                                                "value": 5,
                                                "unit": "half-lives"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Adverse events related to prior anti-cancer treatment related to therapies other than LHRH analogue must have recovered to Grade ≤ 1 with the exception of any grade alopecia.",
                                        "criterion": "adverse events from prior anti-cancer therapies (other than LHRH analogue)",
                                        "requirement": {
                                            "requirement_type": "severity",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 1,
                                                "unit": "Grade"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Adverse events related to prior anti-cancer treatment related to therapies other than LHRH analogue must have recovered to Grade ≤ 1 with the exception of any grade alopecia.",
                                        "criterion": "adverse events from prior anti-cancer therapies (other than LHRH analogue)",
                                        "requirement": {
                                            "requirement_type": "exception",
                                            "expected_value": "alopecia (any grade)"
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Patients receiving enzalutamide prior to study entry may continue treatment at their current enzalutamide dose level without requirement for wash-out period.",
                        "criterion": "enzalutamide treatment prior to study entry",
                        "requirement": {
                            "requirement_type": "continuation allowed",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Serum sodium level >=130 mmol/L.",
                "criterions": [
                    {
                        "exact_snippets": "Serum sodium level >=130 mmol/L",
                        "criterion": "serum sodium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 130,
                                "unit": "mmol/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum sodium level >=130 mmol/L",
                        "criterion": "serum sodium level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 130,
                                "unit": "mmol/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Castrate level of serum testosterone at study entry (<50 ng/dL). Patients without prior bilateral orchiectomy are required to remain on Luteinizing hormone-releasing hormone (LHRH) analogue treatment for duration of study.",
                "criterions": [
                    {
                        "exact_snippets": "Castrate level of serum testosterone at study entry (<50 ng/dL)",
                        "criterion": "serum testosterone",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients without prior bilateral orchiectomy are required to remain on Luteinizing hormone-releasing hormone (LHRH) analogue treatment for duration of study",
                        "criterion": "LHRH analogue treatment",
                        "requirement": {
                            "requirement_type": "continuation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients without prior bilateral orchiectomy are required to remain on Luteinizing hormone-releasing hormone (LHRH) analogue treatment for duration of study",
                        "criterion": "LHRH analogue treatment",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": "patients without prior bilateral orchiectomy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Castrate level of serum testosterone at study entry (<50 ng/dL)",
                        "criterion": "serum testosterone",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Patients without prior bilateral orchiectomy are required to remain on Luteinizing hormone-releasing hormone (LHRH) analogue treatment for duration of study",
                                "criterion": "LHRH analogue treatment",
                                "requirement": {
                                    "requirement_type": "applicability",
                                    "expected_value": "patients without prior bilateral orchiectomy"
                                }
                            },
                            {
                                "exact_snippets": "Patients without prior bilateral orchiectomy are required to remain on Luteinizing hormone-releasing hormone (LHRH) analogue treatment for duration of study",
                                "criterion": "LHRH analogue treatment",
                                "requirement": {
                                    "requirement_type": "continuation",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Hemoglobin >= 8.0 grams per deciliter (g/dL) without red blood cell transfusion during the 14 days prior to first dose of FOR46.",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin >= 8.0 grams per deciliter (g/dL)",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "without red blood cell transfusion during the 14 days prior to first dose of FOR46",
                        "criterion": "red blood cell transfusion",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "without red blood cell transfusion during the 14 days prior to first dose of FOR46",
                        "criterion": "red blood cell transfusion",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "14 days prior to first dose of FOR46"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin >= 8.0 grams per deciliter (g/dL)",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "without red blood cell transfusion during the 14 days prior to first dose of FOR46",
                                "criterion": "red blood cell transfusion",
                                "requirement": {
                                    "requirement_type": "absence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "without red blood cell transfusion during the 14 days prior to first dose of FOR46",
                                "criterion": "red blood cell transfusion",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "14 days prior to first dose of FOR46"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Demonstrates adequate organ function as defined below:",
                "criterions": [
                    {
                        "exact_snippets": "Demonstrates adequate organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Demonstrates adequate organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Participants must be willing to undergo metastatic tumor biopsy during Screening. If there is no safely accessible metastatic lesion, this requirement will be waived.",
                "criterions": [
                    {
                        "exact_snippets": "Participants must be willing to undergo metastatic tumor biopsy during Screening.",
                        "criterion": "willingness to undergo metastatic tumor biopsy",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants must be willing to undergo metastatic tumor biopsy during Screening.",
                        "criterion": "willingness to undergo metastatic tumor biopsy",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": "metastatic tumor biopsy"
                        }
                    },
                    {
                        "exact_snippets": "Participants must be willing to undergo metastatic tumor biopsy during Screening.",
                        "criterion": "willingness to undergo metastatic tumor biopsy",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "during Screening"
                        }
                    },
                    {
                        "exact_snippets": "If there is no safely accessible metastatic lesion, this requirement will be waived.",
                        "criterion": "safely accessible metastatic lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "not_criteria": {
                        "not_criteria": {
                            "exact_snippets": "If there is no safely accessible metastatic lesion, this requirement will be waived.",
                            "criterion": "safely accessible metastatic lesion",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": true
                            }
                        }
                    }
                },
                "then_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Participants must be willing to undergo metastatic tumor biopsy during Screening.",
                            "criterion": "willingness to undergo metastatic tumor biopsy",
                            "requirement": {
                                "requirement_type": "willingness",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "Participants must be willing to undergo metastatic tumor biopsy during Screening.",
                            "criterion": "willingness to undergo metastatic tumor biopsy",
                            "requirement": {
                                "requirement_type": "procedure",
                                "expected_value": "metastatic tumor biopsy"
                            }
                        },
                        {
                            "exact_snippets": "Participants must be willing to undergo metastatic tumor biopsy during Screening.",
                            "criterion": "willingness to undergo metastatic tumor biopsy",
                            "requirement": {
                                "requirement_type": "timing",
                                "expected_value": "during Screening"
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "Must be MALE",
                "criterions": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Eastern Cooperative Oncology Group (ECOG) performance status <= 1 (Karnofsky performance status >= 70 percent (%)).",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status <= 1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Karnofsky performance status >= 70 percent (%)",
                        "criterion": "Karnofsky performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "percent"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status <= 1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Karnofsky performance status >= 70 percent (%)",
                        "criterion": "Karnofsky performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "percent"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Total bilirubin <=1.5 x institutional upper limit of normal (ULN), unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits.",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin <=1.5 x institutional upper limit of normal (ULN)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unless elevated due to Gilbert's syndrome",
                        "criterion": "Gilbert's syndrome",
                        "requirement": {
                            "requirement_type": "cause of elevated bilirubin",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "direct bilirubin is within normal limits",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "within normal limits"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Total bilirubin <=1.5 x institutional upper limit of normal (ULN)",
                            "criterion": "total bilirubin",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 1.5,
                                    "unit": "x ULN"
                                }
                            }
                        },
                        {
                            "not_criteria": {
                                "not_criteria": {
                                    "exact_snippets": "unless elevated due to Gilbert's syndrome",
                                    "criterion": "Gilbert's syndrome",
                                    "requirement": {
                                        "requirement_type": "cause of elevated bilirubin",
                                        "expected_value": true
                                    }
                                }
                            }
                        }
                    ]
                },
                "then_criteria": null,
                "else_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "unless elevated due to Gilbert's syndrome",
                            "criterion": "Gilbert's syndrome",
                            "requirement": {
                                "requirement_type": "cause of elevated bilirubin",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "direct bilirubin is within normal limits",
                            "criterion": "direct bilirubin",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": "within normal limits"
                            }
                        }
                    ]
                }
            }
        },
        {
            "identified_line": {
                "line": "10. Age >=18 years.",
                "criterions": [
                    {
                        "exact_snippets": "Age >=18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age >=18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Platelets >= 100,000/mcL and no platelet transfusions during the 14 days prior to first dose of FOR46.",
                "criterions": [
                    {
                        "exact_snippets": "Platelets >= 100,000/mcL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/mcL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no platelet transfusions during the 14 days prior to first dose of FOR46",
                        "criterion": "platelet transfusions",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no platelet transfusions during the 14 days prior to first dose of FOR46",
                        "criterion": "platelet transfusions",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "during the 14 days prior to first dose of FOR46"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets >= 100,000/mcL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/mcL"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "no platelet transfusions during the 14 days prior to first dose of FOR46",
                                "criterion": "platelet transfusions",
                                "requirement": {
                                    "requirement_type": "absence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "no platelet transfusions during the 14 days prior to first dose of FOR46",
                                "criterion": "platelet transfusions",
                                "requirement": {
                                    "requirement_type": "time frame",
                                    "expected_value": "during the 14 days prior to first dose of FOR46"
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "4. Cardiac condition as defined as one or more of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Cardiac condition as defined as one or more of the following",
                        "criterion": "cardiac condition",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Cardiac condition as defined as one or more of the following",
                        "criterion": "cardiac condition",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Use of a prohibited concomitant medication within 7 days of first dose of FOR46, including:",
                "criterions": [
                    {
                        "exact_snippets": "Use of a prohibited concomitant medication within 7 days of first dose of FOR46",
                        "criterion": "prohibited concomitant medication use",
                        "requirement": {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before first dose of FOR46"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Use of a prohibited concomitant medication within 7 days of first dose of FOR46",
                        "criterion": "prohibited concomitant medication use",
                        "requirement": {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before first dose of FOR46"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Is receiving systemic steroid therapy at a prednisone equivalent dose of > 10 milligram daily or other form of immunosuppressive therapy within 7 days prior to first dose of study drug.",
                "criterions": [
                    {
                        "exact_snippets": "Is receiving systemic steroid therapy at a prednisone equivalent dose of > 10 milligram daily",
                        "criterion": "systemic steroid therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Is receiving systemic steroid therapy at a prednisone equivalent dose of > 10 milligram daily",
                        "criterion": "systemic steroid therapy",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "milligram daily"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Is receiving systemic steroid therapy at a prednisone equivalent dose of > 10 milligram daily",
                        "criterion": "systemic steroid therapy",
                        "requirement": {
                            "requirement_type": "prednisone equivalent",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "or other form of immunosuppressive therapy within 7 days prior to first dose of study drug",
                        "criterion": "immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "or other form of immunosuppressive therapy within 7 days prior to first dose of study drug",
                        "criterion": "immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to first dose of study drug"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Is receiving systemic steroid therapy at a prednisone equivalent dose of > 10 milligram daily",
                                "criterion": "systemic steroid therapy",
                                "requirement": {
                                    "requirement_type": "current use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Is receiving systemic steroid therapy at a prednisone equivalent dose of > 10 milligram daily",
                                "criterion": "systemic steroid therapy",
                                "requirement": {
                                    "requirement_type": "dose",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 10,
                                        "unit": "milligram daily"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Is receiving systemic steroid therapy at a prednisone equivalent dose of > 10 milligram daily",
                                "criterion": "systemic steroid therapy",
                                "requirement": {
                                    "requirement_type": "prednisone equivalent",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "or other form of immunosuppressive therapy within 7 days prior to first dose of study drug",
                                "criterion": "immunosuppressive therapy",
                                "requirement": {
                                    "requirement_type": "current use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "or other form of immunosuppressive therapy within 7 days prior to first dose of study drug",
                                "criterion": "immunosuppressive therapy",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days prior to first dose of study drug"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. History of intracranial hemorrhage.",
                "criterions": [
                    {
                        "exact_snippets": "History of intracranial hemorrhage.",
                        "criterion": "intracranial hemorrhage",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of intracranial hemorrhage.",
                        "criterion": "intracranial hemorrhage",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. History of seizure or pre-disposing condition including:",
                "criterions": [
                    {
                        "exact_snippets": "History of seizure",
                        "criterion": "seizure",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "pre-disposing condition",
                        "criterion": "pre-disposing condition for seizure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of seizure",
                        "criterion": "seizure",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "pre-disposing condition",
                        "criterion": "pre-disposing condition for seizure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Has received prior radiotherapy within 2 weeks of first dose of FOR46.",
                "criterions": [
                    {
                        "exact_snippets": "Has received prior radiotherapy within 2 weeks of first dose of FOR46.",
                        "criterion": "prior radiotherapy",
                        "requirement": {
                            "requirement_type": "time since prior radiotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Has received prior radiotherapy within 2 weeks of first dose of FOR46.",
                        "criterion": "prior radiotherapy",
                        "requirement": {
                            "requirement_type": "time since prior radiotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Prior treatment with FOR46 or another CD46-targeting therapeutic agent.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with FOR46",
                        "criterion": "prior treatment with FOR46",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "another CD46-targeting therapeutic agent",
                        "criterion": "prior treatment with CD46-targeting therapeutic agent",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior treatment with FOR46",
                        "criterion": "prior treatment with FOR46",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "another CD46-targeting therapeutic agent",
                        "criterion": "prior treatment with CD46-targeting therapeutic agent",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.",
                "criterions": [
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study",
                        "criterion": "condition, therapy, or laboratory abnormality",
                        "requirement": {
                            "requirement_type": "potential to confound study results",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, or laboratory abnormality that might ... interfere with the subject's participation for the full duration of the study",
                        "criterion": "condition, therapy, or laboratory abnormality",
                        "requirement": {
                            "requirement_type": "potential to interfere with participation for full duration",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, or laboratory abnormality that ... is not in the best interest of the subject to participate, in the opinion of the treating investigator",
                        "criterion": "condition, therapy, or laboratory abnormality",
                        "requirement": {
                            "requirement_type": "not in best interest to participate (investigator opinion)",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study",
                        "criterion": "condition, therapy, or laboratory abnormality",
                        "requirement": {
                            "requirement_type": "potential to confound study results",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, or laboratory abnormality that might ... interfere with the subject's participation for the full duration of the study",
                        "criterion": "condition, therapy, or laboratory abnormality",
                        "requirement": {
                            "requirement_type": "potential to interfere with participation for full duration",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has a history or current evidence of any condition, therapy, or laboratory abnormality that ... is not in the best interest of the subject to participate, in the opinion of the treating investigator",
                        "criterion": "condition, therapy, or laboratory abnormality",
                        "requirement": {
                            "requirement_type": "not in best interest to participate (investigator opinion)",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. History of unstable angina, myocardial infarction, or cerebrovascular accident within 6 months prior to Cycle 1, Day 1.",
                "criterions": [
                    {
                        "exact_snippets": "History of unstable angina ... within 6 months prior to Cycle 1, Day 1.",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to Cycle 1, Day 1"
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of ... myocardial infarction ... within 6 months prior to Cycle 1, Day 1.",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to Cycle 1, Day 1"
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of ... cerebrovascular accident within 6 months prior to Cycle 1, Day 1.",
                        "criterion": "cerebrovascular accident",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to Cycle 1, Day 1"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of unstable angina ... within 6 months prior to Cycle 1, Day 1.",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to Cycle 1, Day 1"
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of ... myocardial infarction ... within 6 months prior to Cycle 1, Day 1.",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to Cycle 1, Day 1"
                            }
                        }
                    },
                    {
                        "exact_snippets": "History of ... cerebrovascular accident within 6 months prior to Cycle 1, Day 1.",
                        "criterion": "cerebrovascular accident",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to Cycle 1, Day 1"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. History of brain metastasis.",
                "criterions": [
                    {
                        "exact_snippets": "History of brain metastasis.",
                        "criterion": "brain metastasis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "History of brain metastasis.",
                    "criterion": "brain metastasis",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Uncontrolled supraventricular arrhythmia or ventricular arrhythmia requiring treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled supraventricular arrhythmia",
                        "criterion": "supraventricular arrhythmia",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "ventricular arrhythmia requiring treatment",
                        "criterion": "ventricular arrhythmia",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Uncontrolled supraventricular arrhythmia",
                        "criterion": "supraventricular arrhythmia",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "ventricular arrhythmia requiring treatment",
                        "criterion": "ventricular arrhythmia",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Has an active infection requiring intravenous antibiotics within 7 days prior to Cycle 1, Day 1.",
                "criterions": [
                    {
                        "exact_snippets": "Has an active infection requiring intravenous antibiotics within 7 days prior to Cycle 1, Day 1.",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring intravenous antibiotics"
                        }
                    },
                    {
                        "exact_snippets": "Has an active infection requiring intravenous antibiotics within 7 days prior to Cycle 1, Day 1.",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to Cycle 1, Day 1"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Has an active infection requiring intravenous antibiotics within 7 days prior to Cycle 1, Day 1.",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring intravenous antibiotics"
                        }
                    },
                    {
                        "exact_snippets": "Has an active infection requiring intravenous antibiotics within 7 days prior to Cycle 1, Day 1.",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to Cycle 1, Day 1"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. History of pneumonitis.",
                "criterions": [
                    {
                        "exact_snippets": "History of pneumonitis",
                        "criterion": "pneumonitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of pneumonitis",
                        "criterion": "pneumonitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Cerebrovascular accident (CVA) within 6 months prior to study entry.",
                "criterions": [
                    {
                        "exact_snippets": "Cerebrovascular accident (CVA) within 6 months prior to study entry.",
                        "criterion": "cerebrovascular accident (CVA)",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to study entry"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Cerebrovascular accident (CVA) within 6 months prior to study entry.",
                        "criterion": "cerebrovascular accident (CVA)",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to study entry"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",
                "criterions": [
                    {
                        "exact_snippets": "Has known psychiatric or substance abuse disorders",
                        "criterion": "psychiatric disorders",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has known psychiatric or substance abuse disorders",
                        "criterion": "substance abuse disorders",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Has known psychiatric or substance abuse disorders",
                                "criterion": "psychiatric disorders",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Has known psychiatric or substance abuse disorders",
                                "criterion": "psychiatric disorders",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Has known psychiatric or substance abuse disorders",
                                "criterion": "substance abuse disorders",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Has known psychiatric or substance abuse disorders",
                                "criterion": "substance abuse disorders",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "2. Acceptable methods of contraception include continuous total abstinence, or double-barrier method of birth control (e.g. condoms used with spermicide, or condoms used with oral contraceptives). Periodic abstinence and withdrawal are not acceptable methods of contraception.",
                "criterions": [
                    {
                        "exact_snippets": "Acceptable methods of contraception include continuous total abstinence, or double-barrier method of birth control (e.g. condoms used with spermicide, or condoms used with oral contraceptives). Periodic abstinence and withdrawal are not acceptable methods of contraception.",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": [
                                "continuous total abstinence",
                                "double-barrier method of birth control (e.g. condoms used with spermicide, or condoms used with oral contraceptives)"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Acceptable methods of contraception include continuous total abstinence, or double-barrier method of birth control (e.g. condoms used with spermicide, or condoms used with oral contraceptives). Periodic abstinence and withdrawal are not acceptable methods of contraception.",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "unacceptability",
                            "expected_value": [
                                "periodic abstinence",
                                "withdrawal"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Absolute neutrophil count ≥ 1,500/microliter (mcL).",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count ≥ 1,500/microliter (mcL)",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "microliter"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count \u001e 1,500/microliter (mcL)",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "microliter"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. Patients must agree to use adequate contraception prior to the study, for the duration of study participation, and 60 days after last administration of study treatment. Adequate contraception includes:",
                "criterions": [
                    {
                        "exact_snippets": "Patients must agree to use adequate contraception prior to the study, for the duration of study participation, and 60 days after last administration of study treatment.",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients must agree to use adequate contraception prior to the study, for the duration of study participation, and 60 days after last administration of study treatment.",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": [
                                "prior to the study",
                                "for the duration of study participation",
                                "60 days after last administration of study treatment"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Patients must agree to use adequate contraception prior to the study, for the duration of study participation, and 60 days after last administration of study treatment.",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": "adequate"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "14. Individuals with concurrent second malignancy requiring active treatment at study entry. Nonmelanoma skin cancer, non-muscle invasive bladder cancer, and other carcinomas-in-situ are allowable exceptions.",
                "criterions": [
                    {
                        "exact_snippets": "Individuals with concurrent second malignancy requiring active treatment at study entry",
                        "criterion": "concurrent second malignancy",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring active treatment at study entry"
                        }
                    },
                    {
                        "exact_snippets": "Nonmelanoma skin cancer, non-muscle invasive bladder cancer, and other carcinomas-in-situ are allowable exceptions",
                        "criterion": "type of concurrent second malignancy",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": [
                                "nonmelanoma skin cancer",
                                "non-muscle invasive bladder cancer",
                                "other carcinomas-in-situ"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Prior progression by PCWG3 criteria on one or more androgen signaling inhibitors including abiraterone acetate, enzalutamide, apalutamide, and/or darolutamide.",
                "criterions": [
                    {
                        "exact_snippets": "Prior progression by PCWG3 criteria",
                        "criterion": "disease progression by PCWG3 criteria",
                        "requirement": {
                            "requirement_type": "history of progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "on one or more androgen signaling inhibitors including abiraterone acetate, enzalutamide, apalutamide, and/or darolutamide",
                        "criterion": "treatment with androgen signaling inhibitors",
                        "requirement": {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "on one or more androgen signaling inhibitors including abiraterone acetate, enzalutamide, apalutamide, and/or darolutamide",
                        "criterion": "treatment with androgen signaling inhibitors",
                        "requirement": {
                            "requirement_type": "number of agents",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "androgen signaling inhibitor(s)"
                            }
                        }
                    },
                    {
                        "exact_snippets": "on one or more androgen signaling inhibitors including abiraterone acetate, enzalutamide, apalutamide, and/or darolutamide",
                        "criterion": "treatment with androgen signaling inhibitors",
                        "requirement": {
                            "requirement_type": "agent names",
                            "expected_value": [
                                "abiraterone acetate",
                                "enzalutamide",
                                "apalutamide",
                                "darolutamide"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Patients who are sexually active should consider their female partner to be of childbearing potential if she has experienced menarche and is not postmenopausal (defined as amenorrhea > 24 consecutive months) or has not undergone successful surgical sterilization. Even women who use contraceptive hormones (oral, implanted, or injected), an intrauterine device, or barrier methods (diaphragms, condoms, spermicide) should be considered to be of childbearing potential.",
                "criterions": [
                    {
                        "exact_snippets": "female partner ... has experienced menarche",
                        "criterion": "female partner's menarche status",
                        "requirement": {
                            "requirement_type": "has experienced menarche",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "female partner ... is not postmenopausal (defined as amenorrhea > 24 consecutive months)",
                        "criterion": "female partner's menopausal status",
                        "requirement": {
                            "requirement_type": "postmenopausal",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "amenorrhea > 24 consecutive months",
                        "criterion": "female partner's amenorrhea duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 24,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "female partner ... has not undergone successful surgical sterilization",
                        "criterion": "female partner's surgical sterilization status",
                        "requirement": {
                            "requirement_type": "successful surgical sterilization",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Even women who use contraceptive hormones (oral, implanted, or injected), an intrauterine device, or barrier methods (diaphragms, condoms, spermicide) should be considered to be of childbearing potential.",
                        "criterion": "female partner's contraceptive use",
                        "requirement": {
                            "requirement_type": "contraceptive use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "female partner ... has experienced menarche",
                                        "criterion": "female partner's menarche status",
                                        "requirement": {
                                            "requirement_type": "has experienced menarche",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "female partner ... is not postmenopausal (defined as amenorrhea > 24 consecutive months)",
                                        "criterion": "female partner's menopausal status",
                                        "requirement": {
                                            "requirement_type": "postmenopausal",
                                            "expected_value": false
                                        }
                                    },
                                    {
                                        "exact_snippets": "female partner ... has not undergone successful surgical sterilization",
                                        "criterion": "female partner's surgical sterilization status",
                                        "requirement": {
                                            "requirement_type": "successful surgical sterilization",
                                            "expected_value": false
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "Even women who use contraceptive hormones (oral, implanted, or injected), an intrauterine device, or barrier methods (diaphragms, condoms, spermicide) should be considered to be of childbearing potential.",
                                "criterion": "female partner's contraceptive use",
                                "requirement": {
                                    "requirement_type": "contraceptive use",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. No prior taxane-based chemotherapy for the treatment of mCRPC. Prior taxane use in the castration-sensitive prostate cancer (CSPC) setting allowed provided last dose > 6 months prior to study entry.",
                "criterions": [
                    {
                        "exact_snippets": "No prior taxane-based chemotherapy for the treatment of mCRPC.",
                        "criterion": "prior taxane-based chemotherapy for mCRPC",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Prior taxane use in the castration-sensitive prostate cancer (CSPC) setting allowed provided last dose > 6 months prior to study entry.",
                        "criterion": "prior taxane use in CSPC setting",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior taxane use in the castration-sensitive prostate cancer (CSPC) setting allowed provided last dose > 6 months prior to study entry.",
                        "criterion": "prior taxane use in CSPC setting",
                        "requirement": {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "No prior taxane-based chemotherapy for the treatment of mCRPC.",
                            "criterion": "prior taxane-based chemotherapy for mCRPC",
                            "requirement": {
                                "requirement_type": "history of use",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "not_criteria": {
                                    "exact_snippets": "Prior taxane use in the castration-sensitive prostate cancer (CSPC) setting allowed provided last dose > 6 months prior to study entry.",
                                    "criterion": "prior taxane use in CSPC setting",
                                    "requirement": {
                                        "requirement_type": "history of use",
                                        "expected_value": true
                                    }
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Prior taxane use in the castration-sensitive prostate cancer (CSPC) setting allowed provided last dose > 6 months prior to study entry.",
                                        "criterion": "prior taxane use in CSPC setting",
                                        "requirement": {
                                            "requirement_type": "history of use",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Prior taxane use in the castration-sensitive prostate cancer (CSPC) setting allowed provided last dose > 6 months prior to study entry.",
                                        "criterion": "prior taxane use in CSPC setting",
                                        "requirement": {
                                            "requirement_type": "time since last dose",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 6,
                                                "unit": "months"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Patients must be evaluable for the primary endpoint of composite response, and must have either serum PSA ≥ 2 ng/mL during Screening and/or measurable disease by RECIST 1.1 criteria.",
                "criterions": [
                    {
                        "exact_snippets": "Patients must be evaluable for the primary endpoint of composite response",
                        "criterion": "evaluable for primary endpoint of composite response",
                        "requirement": {
                            "requirement_type": "evaluable",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "serum PSA ≥ 2 ng/mL during Screening",
                        "criterion": "serum PSA",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "ng/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "measurable disease by RECIST 1.1 criteria",
                        "criterion": "measurable disease by RECIST 1.1",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients must be evaluable for the primary endpoint of composite response",
                        "criterion": "evaluable for primary endpoint of composite response",
                        "requirement": {
                            "requirement_type": "evaluable",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "serum PSA \u001e 2 ng/mL during Screening",
                                "criterion": "serum PSA",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "ng/mL"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "measurable disease by RECIST 1.1 criteria",
                                "criterion": "measurable disease by RECIST 1.1",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Dose Expansion only: Participants must be willing to undergo CD46-directed Positron Emission Tomography (PET) imaging during Screening (Co-enrolling on NCT05245006, Groups B and C)",
                "criterions": [
                    {
                        "exact_snippets": "Participants must be willing to undergo CD46-directed Positron Emission Tomography (PET) imaging during Screening",
                        "criterion": "willingness to undergo CD46-directed PET imaging",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants must be willing to undergo CD46-directed Positron Emission Tomography (PET) imaging during Screening",
                        "criterion": "willingness to undergo CD46-directed PET imaging",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": "CD46-directed PET imaging"
                        }
                    },
                    {
                        "exact_snippets": "Participants must be willing to undergo CD46-directed Positron Emission Tomography (PET) imaging during Screening",
                        "criterion": "willingness to undergo CD46-directed PET imaging",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "during Screening"
                        }
                    },
                    {
                        "exact_snippets": "Co-enrolling on NCT05245006, Groups B and C",
                        "criterion": "co-enrollment on NCT05245006, Groups B and C",
                        "requirement": {
                            "requirement_type": "co-enrollment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Co-enrolling on NCT05245006, Groups B and C",
                        "criterion": "co-enrollment on NCT05245006, Groups B and C",
                        "requirement": {
                            "requirement_type": "study",
                            "expected_value": "NCT05245006"
                        }
                    },
                    {
                        "exact_snippets": "Co-enrolling on NCT05245006, Groups B and C",
                        "criterion": "co-enrollment on NCT05245006, Groups B and C",
                        "requirement": {
                            "requirement_type": "groups",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "a. Strong inhibitor of CYP3A4 (boceprevir, clarithromycin, cobicistat, conivaptan, diltiazem, danoprevir/ritonavir, elvitegravir/ritonavir, grapefruit juice, idelalisib, indinavir/ritonavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, paritaprevir/ritonavir/ombitasvir and/or dasabuvir, posaconazole, ritonavir, saquinavir/ritonavir, tipranavir/ritonavir, troleandomycin, and voriconazole).",
                "criterions": [
                    {
                        "exact_snippets": "Strong inhibitor of CYP3A4 (boceprevir, clarithromycin, cobicistat, conivaptan, diltiazem, danoprevir/ritonavir, elvitegravir/ritonavir, grapefruit juice, idelalisib, indinavir/ritonavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, paritaprevir/ritonavir/ombitasvir and/or dasabuvir, posaconazole, ritonavir, saquinavir/ritonavir, tipranavir/ritonavir, troleandomycin, and voriconazole)",
                        "criterion": "CYP3A4 inhibitor use",
                        "requirement": {
                            "requirement_type": "strength",
                            "expected_value": "strong"
                        }
                    },
                    {
                        "exact_snippets": "Strong inhibitor of CYP3A4 (boceprevir, clarithromycin, cobicistat, conivaptan, diltiazem, danoprevir/ritonavir, elvitegravir/ritonavir, grapefruit juice, idelalisib, indinavir/ritonavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, paritaprevir/ritonavir/ombitasvir and/or dasabuvir, posaconazole, ritonavir, saquinavir/ritonavir, tipranavir/ritonavir, troleandomycin, and voriconazole)",
                        "criterion": "CYP3A4 inhibitor use",
                        "requirement": {
                            "requirement_type": "agent",
                            "expected_value": [
                                "boceprevir",
                                "clarithromycin",
                                "cobicistat",
                                "conivaptan",
                                "diltiazem",
                                "danoprevir/ritonavir",
                                "elvitegravir/ritonavir",
                                "grapefruit juice",
                                "idelalisib",
                                "indinavir/ritonavir",
                                "itraconazole",
                                "ketoconazole",
                                "lopinavir/ritonavir",
                                "nefazodone",
                                "nelfinavir",
                                "paritaprevir/ritonavir/ombitasvir and/or dasabuvir",
                                "posaconazole",
                                "ritonavir",
                                "saquinavir/ritonavir",
                                "tipranavir/ritonavir",
                                "troleandomycin",
                                "voriconazole"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Prior histologic evidence of de novo or treatment-emergent small cell neuroendocrine prostate cancer. Pathologic assessment of baseline tumor biopsy performed during Screening is not required for determination of study eligibility.",
                "criterions": [
                    {
                        "exact_snippets": "Prior histologic evidence of de novo or treatment-emergent small cell neuroendocrine prostate cancer",
                        "criterion": "small cell neuroendocrine prostate cancer",
                        "requirement": {
                            "requirement_type": "histologic evidence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior histologic evidence of de novo or treatment-emergent small cell neuroendocrine prostate cancer",
                        "criterion": "small cell neuroendocrine prostate cancer",
                        "requirement": {
                            "requirement_type": "disease origin",
                            "expected_value": [
                                "de novo",
                                "treatment-emergent"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Pathologic assessment of baseline tumor biopsy performed during Screening is not required for determination of study eligibility",
                        "criterion": "pathologic assessment of baseline tumor biopsy during Screening",
                        "requirement": {
                            "requirement_type": "requirement for eligibility",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. New York Heart Association (NYHA) congestive heart failure class III or IV.",
                "criterions": [
                    {
                        "exact_snippets": "New York Heart Association (NYHA) congestive heart failure class III or IV",
                        "criterion": "congestive heart failure (NYHA class)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": [
                                "class III",
                                "class IV"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "10. Major surgery within 28 days prior to Cycle 1, Day 1. Minor procedures including biopsies, dental surgery, cataract surgery, or outpatient procedure are allowed.",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery within 28 days prior to Cycle 1, Day 1.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Major surgery within 28 days prior to Cycle 1, Day 1.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "timing reference",
                            "expected_value": "prior to Cycle 1, Day 1"
                        }
                    },
                    {
                        "exact_snippets": "Minor procedures including biopsies, dental surgery, cataract surgery, or outpatient procedure are allowed.",
                        "criterion": "minor procedures (including biopsies, dental surgery, cataract surgery, or outpatient procedure)",
                        "requirement": {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Major surgery within 28 days prior to Cycle 1, Day 1.",
                                "criterion": "major surgery",
                                "requirement": {
                                    "requirement_type": "time since procedure",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Major surgery within 28 days prior to Cycle 1, Day 1.",
                                "criterion": "major surgery",
                                "requirement": {
                                    "requirement_type": "timing reference",
                                    "expected_value": "prior to Cycle 1, Day 1"
                                }
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Minor procedures including biopsies, dental surgery, cataract surgery, or outpatient procedure are allowed.",
                            "criterion": "minor procedures (including biopsies, dental surgery, cataract surgery, or outpatient procedure)",
                            "requirement": {
                                "requirement_type": "allowance",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}